Wordt geladen...
Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience
OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. A single Latin American center experience was reviewed to determine the safety and efficacy of a...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer International Publishing
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3585834/ https://ncbi.nlm.nih.gov/pubmed/23199211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2165/11636760-000000000-00000 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|